Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib PK and Safety in Chinese Patients
NCT03788603Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rogaratinib in solid tumor, sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events (Frequency), Treatment-Emergent Adverse Events (Severity) and 4 more. Started Jan 2019; status: completed.
02
Drugs
rogaratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03788603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788603.